AUS
NZ
UK
CA
USA
IND
Clarity Pharmaceuticals (ASX:CU6) has received a significant boost with the FDA granting 'Fast Track' designation to its new imaging agent, 64Cu-SAR-bisPSMA, designed for detecting prostate cancer. This designation is set to accelerate the development and regulatory review process for the drug, allowing Clarity to submit parts of its application as they are completed and engage more frequently with the FDA. This expedited process is expected to shorten the time required to bring this innovative diagnostic tool to market.
The 64Cu-SAR-bisPSMA has shown promising results in previous studies, including the Phase I PROPELLER study, which highlighted its safety and efficacy. Clarity has already initiated a registrational Phase III trial named CLARIFY and is planning a second Phase III trial based on positive results from earlier research.
Dr. Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, expressed enthusiasm about the designation, noting, “The designation will allow us to work closely with the FDA to facilitate the development process, potentially accelerating the approval of this best-in-class diagnostic.” The 64Cu-SAR-bisPSMA’s dual-targeting structure and longer half-life offer notable advantages over existing diagnostics, such as improved tumor uptake and longer shelf life, which could enhance accuracy and accessibility in prostate cancer management.
Next Science Limited (ASX:NXS) has revised its financial outlook for FY24, announcing that it will not provide revenue guidance for the year. The company, known for its XBIO suite designed to combat biofilm-based infections, has encountered delays with its new sales strategy, impacting its revenue forecasts.
Despite the guidance revision, Next Science anticipates achieving cash flow positivity in the fourth quarter of FY24 or the first quarter of FY25 and expects to be EBITDA positive on an adjusted basis during the same period. CEO I.V. Hall highlighted that the sales reorganisation aims to drive efficiencies and maximize revenue potential within the existing customer base while accessing new opportunities. Hall also pointed out that a flexible cost structure and potential additional funding from a US$5 million loan could support future growth.
The announcement led to a 10% drop in Next Science’s share price this morning. The company’s updated strategy focuses on streamlining operations and boosting revenue potential, positioning itself for future growth despite the current challenges.
